IMPORTANT INFORMATION

  • CFTR.info is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.

ABBREVIATED TERMS & CONDITIONS

  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.

 

I have read and understood the above

Drug research and development » Pre-clinical development » Pre-clinical validation of CFTR therapies

Pre-clinical validation of CFTR therapies

A microbiologist testing medicine in a laboratoryPrior to validation in clinical trials, CFTR-modulating therapies and other therapies need to be validated in pre-clinical models.1 This is to ensure that only the best candidates are investigated in patients.1 The possible models include ex vivo in native tissue from CF patients and cellular models.1

Current animal murine models have limited significance. This partly due to murine and human CFTR channels exhibiting different characteristics and are regulated in a different manner. In addition, mouse models lacking functional CFTR do not develop the characteristic manifestations of CF as observed in humans.1

For CFTR-repairing molecules, efficacy testing on human bronchial epithelial (HBE) cells is considered to be the ‘gold standard’. While this was successfully used for validation of the VX-770 modulator and correlated well with its efficacy in clinical trials, validation with additional compounds is required to demonstrate that efficacy in HBE cells correlates with clinical efficacy in vivo.1

References
  1. Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther 2015;145:19-34.